Of course further studies are warranted, the results were outstanding; more research to make it more effective.
The results showed that anatabine reduced the patients'
immune reaction against their own thyroid gland. Patients taking anatabine had
a significantly greater reduction from baseline in serum thyroglobulin antibody
levels compared to patients on placebo (p= 0.027). Similarly, more patients in
the anatabine group had a greater than 20% drop in thyroglobulin antibodies than
patients on placebo (p=0.023). Finally, the percentage of patients on anatabine
with reductions in thyroglobulin antibodies of at least 25, 50, 75, or 100 WHO
units was significantly greater than that of patients on placebo (all p
most of the events were resolved with simple dose adjustment. As the doctors receive more feedback they'll figure out the optimal dosage level to mitigae "side effects". Given most drugs on the market, these side effects are benign. Great day for those suffering from thyroid disease; now there is a safe, effective option on the market backed by scientific research
Controlled release, hmmm I wonder what they have in mind? LOL!!!!!
5. A controlled release formulation comprising a salt of claim 1 and a biodegradable polymer.
6. The controlled release formulation of claim 5 wherein the biodegradable polymer is selected from the group consisting of poly(orthoesters), poly(anhydrides), and combinations thereof.
7. An extended release formulation comprising a salt of claim 1 and a swellable polymer.
8. The extendedT release formulation of claim 7 wherein the swellable polymer is selected from the group consistin
You left off one other fact regarding UV syudies; in the release about the preclinical data it was mentioned they believed the MOA was discovered and that further studies would be implemented. If the MOA has in fact been discovered, and patent protection is in place, then let the line-up of partnerships begin.